Memorial Sloan Kettering Cancer Center (MSK)-developed Burtomab has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for the treatment of pediatric patients with relapsed or refractory neuroblastoma with central nervous system or leptomeningeal metastasis.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Neuroblastoma is a type of cancer that is formed in certain types of nerve tissue.

Licensed to clinical-stage biopharmaceutical company Y-mAbs Therapeutics, Burtomab is a drug used to treat patients with metastatic neuroblastoma.

YmAbs founder, president and business development and strategy head Thomas Gad said: “We are very pleased that the FDA has granted the breakthrough therapy designation to burtomab and thereby shortened the timelines for making this therapy available to the children facing an unmet medical need.

“Burtomab clearly provides a potential curative treatment option for pediatric patients otherwise faced with little or no options.”

“Burtomab clearly provides a potential curative treatment option for pediatric patients otherwise faced with little or no options.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This is an important milestone achievement for YmAbs, and we continue to work with our strategic partner MSK and the regulatory authorities to advance burtomab to patients suffering from refractory leptomeningeal metastasis from neuroblastoma as quickly as possible.”

MSK Neuroblastoma Programme head Nai-Kong Cheung has developed and tested the antibody that resulted in the breakthrough therapy designation.

The FDA has granted the breakthrough therapy designation based on the data obtained from a pivotal clinical study of burtomab with radio-labelled iodine for the treatment of neuroblastoma that metastasises to the central nervous system or the leptomeninges.

Image: Microscopic view of a typical neuroblastoma with rosette formation. Photo: courtesy of Dr Maria Tsokos, National Cancer Institute.